Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 1717-1720, April 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huber, K.
Right arrow Articles by Binder, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huber, K.
Right arrow Articles by Binder, B. R.

Determination of Plasma Urokinase-type Plasminogen Activator Antigen in Patients with Primary Liver Cancer: Characterization as Tumor-associated Antigen and Comparison with {alpha}-Fetoprotein1

Kurt Huber2, Johannes C. Kirchheimer, Dorothea Ermler, Cameron Bell and Bernd R. Binder

Laboratory for Clinical Experimental Physiology [K. H., J. C. K., C. B., B. R. B.] and the Second Department of Gastroenterology and Hepatology [K. H., D. E], University of Vienna, Austria

We determined the plasma levels of urokinase-type plasminogen activator (u-PA) antigen and {alpha}-fetoprotein (AFP) in 44 patients with different stages of liver cirrhosis and in 29 patients with liver cirrhosis-based primary liver cancer at the time of first clinical detection of the malignant disease. Sensitivity values of u-PA and AFP in detecting primary liver cancer were 57 and 62%, respectively, and specificity values were 95 and 86%, respectively. A combination of both markers led to a significant increase of sensitivity to 89.7%. The specificity of the combination of both markers was 97.3%. In tumor patients with unilocular disease and tumor patients with multicentric disease and/or metastatic spread, similar sensitivity values could be obtained with both markers. Therefore, a combination of u-PA and AFP can increase the accuracy of detection of primary liver cancer, especially in chronic liver diseases known to be predisposing for primary liver cancer, e.g., liver cirrhosis of long duration.

1 Supported by grants from the Austrian Federal Bank (P2330) and the Austrian Funds for the Promotion of Scientific Research (P6832 and P8011).

2 To whom requests for reprints should be addressed, at Laboratory for Clin. Exp. Physiology, University of Vienna, Schwarzspanierstr. 17, A-1090 Vienna, Austria.

Received 9/ 5/91. Accepted 1/17/92.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.